Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology.

PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy. Astatine-211 for PSMA-targeted -radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging. Several peptidomimetic inhibitors of PSMA (such as PSMA-11, PSMA-617, PSMA I&T, MIP-1095, DCFPyL, etc.) typically having a Glu-ureido component that serves as the PSMA binding motif have been designed and translated for routine clinical use [[4], [7]-[9]]. [Extracted from the article]